CLINICAL TRIALS PROFILE FOR LOVAZA
✉ Email this page to a colleague
All Clinical Trials for LOVAZA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00246636 ↗ | Evaluation of Efficacy and Safety of Omacor (Omega-3-acid Ethyl Esters) as Add-on Therapy in Hypertriglyceridemic Subjects Treated With Antara (Fenofibrate) Followed by an 8-week Extension | Completed | GlaxoSmithKline | Phase 4 | 2005-10-01 | The purpose of OM5/LOV111859 was to evaluate efficacy and safety of Omacor (omega-3-acid ethyl esters) as add-on therapy to Antara (fenofibrate) and diet for the treatment of patients with very high triglycerides. The purpose of both OM5X/LOV111860 was to assess the continued efficacy and safety of adjunctive Lovaza (omega-3-acid ethyl esters) therapy in hypertriglyceridemic subjects treated with fenofibrate in lowering serum triglyceride (TG) levels. |
| NCT00246701 ↗ | Evaluation of Efficacy and Safety of Combined Omacor (Omega-3-acid Ethyl Esters) and Simvastatin Therapy in Hypertriglyceridemic Subjects | Completed | GlaxoSmithKline | Phase 3 | 2005-11-01 | The purpose of OM6 is to evaluate efficacy and safety of Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor] combined with simvastatin for lowering non-high-density lipoprotein cholesterol (non-HDL-C) in subjects with persistent high triglycerides despite statin therapy. Additionally, a two-year extension trial (LOV111818/OM6X) is posted on NCT00903409. |
| NCT00346697 ↗ | Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients | Completed | GlaxoSmithKline | Phase 4 | 2006-10-01 | The purpose of this study is to evaluate the efficacy and safety of omega-3-fatty acids in HIV-infected patients with hypertriglyceridemia. In addition, we, the researchers, will evaluate the effect of omega-3 fatty acid administration of markers of bone turnover and inflammation. |
| NCT00346697 ↗ | Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients | Completed | National Center for Complementary and Integrative Health (NCCIH) | Phase 4 | 2006-10-01 | The purpose of this study is to evaluate the efficacy and safety of omega-3-fatty acids in HIV-infected patients with hypertriglyceridemia. In addition, we, the researchers, will evaluate the effect of omega-3 fatty acid administration of markers of bone turnover and inflammation. |
| NCT00346697 ↗ | Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients | Completed | Brown, Todd, M.D., Ph.D. | Phase 4 | 2006-10-01 | The purpose of this study is to evaluate the efficacy and safety of omega-3-fatty acids in HIV-infected patients with hypertriglyceridemia. In addition, we, the researchers, will evaluate the effect of omega-3 fatty acid administration of markers of bone turnover and inflammation. |
| NCT00402363 ↗ | Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation | Completed | GlaxoSmithKline | Phase 3 | 2006-11-01 | The purpose of this study is to evaluate efficacy and safety of Omacor (omega-3-acid ethyl esters) in patients with recurrent, symptomatic atrial fibrillation. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for LOVAZA
Condition Name
Clinical Trial Locations for LOVAZA
Trials by Country
Clinical Trial Progress for LOVAZA
Clinical Trial Phase
Clinical Trial Sponsors for LOVAZA
Sponsor Name
